MedTrace Logo

Evaluating the Safety and Pharmacokinetics of ABT-414 for Subjects With Glioblastoma Multiforme

NCT01800695 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 202

Last updated 2017-11-21

No results posted yet for this study

Summary

This study is evaluating the safety and pharmacokinetics of ABT-414 in subjects with glioblastoma multiforme.

Conditions

Interventions

DRUG

ABT-414

ABT-414 will be administered by intravenous infusion

DRUG

Temozolomide

Temozolomide will be administered per label and local prescribing regulations.

RADIATION

Whole Brain Radiation

Whole Brain radiation will be administered in 30 fractions.

Sponsors & Collaborators

Principal Investigators

  • Earle Bain, MD · AbbVie

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-02
Primary Completion
2017-06-19
Completion
2017-06-19

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01800695 on ClinicalTrials.gov